Shkreli: Price Increase Has Stuck, Happy With That

The transcript covers a discussion with Martin Shkreli about the controversial price increase of Daraprim, its impact on investors, and the political and media backlash. Shkreli defends his actions as a business strategy and discusses the broader context of healthcare costs. He also addresses legal challenges he faces, expressing confidence in his defense.

What challenges did the speaker face in balancing capitalism with running a company?

How did the speaker perceive the role of the media in shaping the narrative around drug pricing?

What are the implications of drug pricing on healthcare costs as discussed in the text?